AbbVie, Halozyme Collaborate

Under their global collaboration and licensing agreement, AbbVie has agreed to pay Halogen an initial $23 million upfront, followed by payments tied to achieving development, regulatory, and sales-based milestones, totaling about $130 million for each of up to nine collaboration targets.

In addition, AbbVie agreed to pay Halozyme tiered royalties if products under the collaboration are commercialized.

ENHANZE™ is based on a recombinant human hyaluronidase or rHuPH20 that aids in the dispersion and absorption of other injected therapeutic drugs by temporarily degrading hyaluronan.

AbbVie reasons that the platform may enable more rapid delivery of injectable medications through subcutaneous delivery. The platform also holds potential for benefiting users of subcutaneous biologics by reducing the need for multiple injections.

Helen Torley, M.B., Ch.B., Halozyme’s president and CEO, said in a statement that AbbVie joins several biopharma giants in partnering with Halozyme to develop new formulations of their drugs. These companies include Baxter International, Johnson & Johnson’s Janssen Biotech, Pfizer, and Roche.

RELATED ARTICLES

Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.

A particular hydrogel, a self-assembling multidomain peptide (MDP) with the amino acid sequence K2(SL)6K2, is bioactive. Researchers found that even without additives their MDP is rapidly infiltrated by host cells, provokes a temporary inflammatory response, does not develop a fibrous capsule, supports the infiltration of a mature vascular network and recruits nerve fibers.

Creating enough nanovesicles to inexpensively serve as a drug delivery system may be as simple as putting the cells through a sieve, according to an international team of researchers who used mouse autologous — their own — immune cells to create large amounts of fillable nanovesicles to deliver drugs to tumors in mice.